Global Bone Morphogenetic Protein Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 - 2023

  • ID: 4279512
  • Report
  • Region: Global
  • 140 Pages
  • Occams Business Research and Consulting
1 of 4
The Bone Morphogenetic Protein Market is Expected to Grow With a CAGR 3.1%

FEATURED COMPANIES

  • Biovision (U.S.)
  • Depuy Synthesis ( U.K.)
  • Genscript (China)
  • Medtronic Inc. (Ireland)
  • Mybiosource (U.S.)
  • Novus Biological (U.S.)
  • MORE

Bone Morphogenetic Proteins (BMP) are a set of proteins that originate from the human body. Bone morphogenetic proteins are responsible for growth and play a significant role in the maintenance, repair and regulation of bone formation. Bone morphogenetic method helps in the formation of new bones and in the process of bone harvesting. BMP products increase the demand for the bone morphogenetic market as it reduces healing time. The bone morphogenetic proteins market is growing at a fast pace due to the rise in sports and road accidents injuries. The rising number of people who are suffering from spinal injuries together with a rise in surgical rates are primary drivers for the market. According to the National spinal cord injury statistical center, approx 314 million people in the U.S. suffered from spinal cord injuries in 2016.

The global bone morphogenetic protein market has enormous opportunity to increase its demand in emerging countries. The major challenge is the lack of professionals in the field of bone morphogenetic protein market, hampering the BMP market growth.The global bone morphogenetic proteins market is segmented on the basis of type and application. On the basis of type, the global bone morphogenetic protein market is sub divided into recombinant bone morphogenetic protein-7 (rhBMP-7) and recombinant bone morphogenetic protein-2 (rhBMP-2). On the basis of application, the bone morphogenetic proteins market is sub divided into oral maxillofacial surgery, spinal fusion, reconstructive and trauma. Spinal fusion segment shows the largest market share globally due to various factors such as increasing demand for minimally invasive medical procedures, rise in sports injuries, rise in spinal injuries and the growing geriatric population etc.

Geographically, the global bone morphogenetic protein market is bifurcated into North America, Europe, Asia Pacific and Rest of the world. North America is the leading region for the bone morphogenetic protein market followed by Europe. Factors driving demand of bone morphogenetic market are awareness of protein product, adoption of new technology by orthopedic surgeons, increase in geriatric population, prevalence of unhealthy lifestyle and increase in the incidence of spinal injuries.

Some of the key players in the bone morphogenetic protein market are ProSpec; DePuySynthes; Medtronic; R&D Systems; Cellumed Co. Ltd.; Sigma-Aldrich Corporation; and Ember Therapeutics Inc. These companies are using various strategies such as merger, joint venture, acquisition, partnership and product launching to sustain in the market.



Note:
Please allow up to 72 hours for delivery.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biovision (U.S.)
  • Depuy Synthesis ( U.K.)
  • Genscript (China)
  • Medtronic Inc. (Ireland)
  • Mybiosource (U.S.)
  • Novus Biological (U.S.)
  • MORE

1. Introduction
1.1. Executive Summary
1.2. Estimation Methodology

2. Market Overview
2.1. Global Bone Morphogenetic Protein Market: Evolution & Transition
2.2. Market Definition & Scope
2.3. Industry Structure
2.4. Regulatory Framework
2.5. Total Market Analysis
2.5.1. Top 5 Findings
2.5.2. Top 5 Opportunity Markets
2.5.3. Top 5 Companies
2.5.4. Top 3 Competitive Strategies
2.6. Estimation Analysis
2.7. Strategic Analysis
2.7.1. Investment Vs. Adoption Model
2.7.2. 360-Degree Industry Analysis
2.7.3. Porters 5 Force Model
2.7.4. See-Saw Analysis
2.7.5. Consumer Analysis And Key Buying Criteria
2.8. Competitive Analysis
2.8.1. Key Strategies & Analysis
2.8.2. Market Share
2.8.3. Top Company Analysis
2.9. Strategic Recommendations & Key Conclusions
2.9.1. Investment Opportunities By Regions
2.9.2. Opportunities in Emerging Applications
2.9.3. Investment Opportunity in Fastest Growing Segment

3. Market Determinants
3.1. Market Drivers
3.1.1. Growing Geriatric Population
3.1.2. Increasing Incidence of Sports-Related Injuries
3.1.3. Increasing Demand for Minimally Invasive Medical Procedures
3.1.4. Increase in Orthopedic Injury And Road Accident Injury
3.1.5. Technological Advancements
3.2. Market Restraints
3.2.1. Availability of Alternative Treatments
3.2.2. High Cost of Procedure
3.3. Market Opportunities
3.3.1. Growing Investment Potential
3.3.2. Awareness Programs
3.4.   Market Challenges
3.4.1. Lack of Professionals

4. Market Segmentation
4.1. Global Bone Morphogenetic Protein Market By Type 2014-2023 ($ Million)
4.1.1. Market Definition And Scope
4.1.2. Decision Support Database & Estimation Methodology
4.1.3. Comparative Analysis Across Market Segments
4.1.4. Opportunity Matrix
4.1.5. Market Segmentation
4.1.5.1. Global Rhbmp-2 Bone Morphogenetic Protein Market
4.1.5.1.1. Application
4.1.5.1.2. Adoption Scenario & Market Determinants
4.1.5.1.3. Market Estimations And Forecasts 2014-2023 ($ Million)
4.1.5.1.4. Top Players & Key Products
4.1.5.1.5. Key Conclusions
4.1.5.2. Global Rhbmp-7 Bone Morphogenetic Protein Market
4.1.5.2.1. Application
4.1.5.2.2. Adoption Scenario & Market Determinants
4.1.5.2.3. Market Estimations And Forecasts 2014-2023 ($ Million)
4.1.5.2.4. Top Players & Key Products
4.1.5.2.5. Key Conclusions
4.2. Global Bone Morphogenetic Protein Market By Application 2014-2023 ($ Million)
4.2.1.1.1. Market Definition And Scope
4.2.1.1.2. Decision Support Database & Estimation Methodology
4.2.1.1.3. Comparative Analysis Across Market Segments
4.2.1.1.4. Opportunity Matrix
4.2.1.1.5. Market Segmentation
4.2.1.2. Global Spinal Fusion Bone Morphogenetic Protein Market
4.2.1.2.1. Adoption Scenario & Market Determinants
4.2.1.2.2. Market Estimations And Forecasts 2014-2023 ($ Million)
4.2.1.2.3. Top Players & Key Products
4.2.1.2.4. Key Conclusions
4.2.1.3. Global Trauma Bone Morphogenetic Protein Market
4.2.1.3.1. Adoption Scenario & Market Determinants
4.2.1.3.2. Market Estimations And Forecasts 2014-2023 ($ Million)
4.2.1.3.3. Top Players & Key Products
4.2.1.3.4. Key Conclusions
4.2.1.4. Global Reconstructive Surgery Bone Morphogenetic Protein Market
4.2.1.4.1. Adoption Scenario & Market Determinants
4.2.1.4.2. Market Estimations And Forecasts 2014-2023 ($ Million)
4.2.1.4.3. Top Players & Key Products
4.2.1.4.4. Key Conclusions
4.2.1.5. Global Oral-Maxillofacial Bone Morphogenetic Protein Market
4.2.1.5.1. Adoption Scenario & Market Determinants
4.2.1.5.2. Market Estimations And Forecasts 2014-2023 ($ Million)
4.2.1.5.3. Top Players & Key Products
4.2.1.5.4. Key Conclusions

5. Competitive Landscape
5.1. Key Strategies
5.1.1. List of Mergers & Acquisition
5.1.2. Lis/T of Joint Ventures
5.1.3. List of Product Launches
5.1.4. List of Partnerships
5.2. Top 10 Company Analysis

6. Global Bone Morphogenetic Protein Market By Region
6.1. Decision Support Database & Estimation Methodology
6.2. Comparative Analysis Across Market Segments
6.3. Opportunity Matrix
6.4.  Geographic Segmentation
6.4.1. North America
6.4.1.1. Industry Application Analysis
6.4.1.2. Top Country Analysis
6.4.1.2.1. U.S.
6.4.1.2.1.1. Market Estimations And Forecasts 2014-2023 ($ Million)
6.4.1.2.1.2. Top Players & Key Products
6.4.1.2.1.3. Key Conclusions
6.4.1.2.2. Canada
6.4.1.2.2.1. Market Estimations And Forecasts 2014-2
6.4.1.2.2.2. Top Players & Key Products
6.4.1.2.2.3. Key Conclusions
6.4.2. Europe
6.4.2.1. Industry Application Analysis
6.4.2.2. Top Country Analysis
6.4.2.2.1. Uk
6.4.2.2.1.1. Market Estimations And Forecasts 2014-2
6.4.2.2.1.2. Top Players & Key Products
6.4.2.2.1.3. Key Conclusions
6.4.2.2.2. France
6.4.2.2.2.1. Market Estimations And Forecasts 2014-2
6.4.2.2.2.2. Top Players & Key Products
6.4.2.2.2.3. Key Conclusions
6.4.2.2.3. Germany
6.4.2.2.3.1. Market Estimations And Forecasts 2014-2
6.4.2.2.3.2. Top Players & Key Products
6.4.2.2.3.3. Key Conclusions
6.4.2.2.4. Spain
6.4.2.2.4.1. Market Estimations And Forecasts 2014-2
6.4.2.2.4.2. Top Players & Key Products
6.4.2.2.4.3. Key Conclusions
6.4.2.2.5. Rest of Europe
6.4.2.2.5.1. Market Estimations And Forecasts 2014-2
6.4.2.2.5.2. Top Players & Key Products
6.4.2.2.5.3. Key Conclusions
6.4.3. Asia Pacific
6.4.3.1. Industry Application Analysis
6.4.3.2. Top Country Analysis
6.4.3.2.1. China
6.4.3.2.1.1. Market Estimations And Forecasts 2014-2
6.4.3.2.1.2. Top Players & Key Products
6.4.3.2.1.3. Key Conclusions
6.4.3.2.2. India
6.4.3.2.2.1. Market Estimations And Forecasts 2014-2
6.4.3.2.2.2. Top Players & Key Products
6.4.3.2.2.3. Key Conclusions
6.4.3.2.3. Japan
6.4.3.2.3.1. Market Estimations And Forecasts 2014-2
6.4.3.2.3.2. Top Players & Key Products
6.4.3.2.3.3. Key Conclusions
6.4.3.2.4. Australia
6.4.3.2.4.1. Market Estimations And Forecasts 2014-2
6.4.3.2.4.2. Top Players & Key Products
6.4.3.2.4.3. Key Conclusions
6.4.3.2.5. Rest of Asia Pacific
6.4.3.2.5.1. Market Estimations And Forecasts 2014-2
6.4.3.2.5.2. Top Players & Key Products
6.4.3.2.5.3. Key Conclusions
6.4.4. Row
6.4.4.1. Industry Application Analysis
6.4.4.2. Top Country Analysis
6.4.4.2.1. Latin America
6.4.4.2.1.1. Market Estimations And Forecasts 2014-2
6.4.4.2.1.2. Top Players & Key Products
6.4.4.2.1.3. Key Conclusions
6.4.4.2.2. Middle East & Africa
6.4.4.2.2.1. Market Estimations And Forecasts 2014-2
6.4.4.2.2.2. Top Players & Key Products
6.4.4.2.2.3. Key Conclusions

7. Company Profiles
7.1.  Cellumed Co. Ltd (South Korea)
7.1.1. Overview
7.1.2. Product Portfolio
7.1.3. Key Innovation Sector
7.1.4. Strategic Initiatives
7.1.5. Scot Analysis
7.1.6. Strategic Analysis
7.2. Stryker Corporation (U.S.)
7.2.1. Overview
7.2.2. Product Portfolio
7.2.3. Key Innovation Sector
7.2.4. Strategic Initiatives
7.2.5. Scot Analysis
7.2.6. Strategic Analysis
7.3. Sigma Aldrich Corporation (U.S.)
7.3.1. Overview
7.3.2. Product Portfolio
7.3.3. Key Innovation Sector
7.3.4. Strategic Initiatives
7.3.5. Scot Analysis
7.3.6. Strategic Analysis
7.4. Medtronic Inc. (Ireland)
7.4.1. Overview
7.4.2. Product Portfolio
7.4.3. Key Innovation Sector
7.4.4. Strategic Initiatives
7.4.5. Scot Analysis
7.4.6. Strategic Analysis
7.5. Prospec  (U.K.)
7.5.1. Overview
7.5.2. Product Portfolio
7.5.3. Key Innovation Sector
7.5.4. Strategic Initiatives
7.5.5. Scot Analysis
7.5.6. Strategic Analysis
7.6.  Ember Therapeutics Inc. (U.S.)
7.6.1. Overview
7.6.2. Product Portfolio
7.6.3. Key Innovation Sector
7.6.4. Strategic Initiatives
7.7. R&D Systems (U.S.)
7.7.1. Overview
7.7.2. Product Portfolio
7.7.3. Key Innovation Sector
7.7.4. Strategic Initiatives
7.7.5. Scot Analysis
7.7.6. Strategic Analysis
7.8. Depuy Synthesis ( U.K.)
7.8.1. Overview
7.8.2. Product Portfolio
7.8.3. Key Innovation Sector
7.8.4. Strategic Initiatives
7.8.5. Scot Analysis
7.8.6. Strategic Analysis
7.9. Thermo Fischer Scientific (U.S.)
7.9.1. Overview
7.9.2. Product Portfolio
7.9.3. Key Innovation Sector
7.9.4. Strategic Initiatives
7.9.5. Scot Analysis
7.9.6. Strategic Analysis
7.10. Novus Biological (U.S.)
7.10.1. Overview
7.10.2. Product Portfolio
7.10.3. Key Innovation Sector
7.10.4. Strategic Initiatives
7.10.5. Scot Analysis
7.10.6. Strategic Analysis
7.11. Genscript (China)
7.11.1. Overview
7.11.2. Product Portfolio
7.11.3. Key Innovation Sector
7.11.4. Strategic Initiatives
7.11.5. Scot Analysis
7.11.6. Strategic Analysis
7.12. Sinobiological (China)
7.12.1. Overview
7.12.2. Product Portfolio
7.12.3. Key Innovation Sector
7.12.4. Strategic Initiatives
7.12.5. Scot Analysis
7.13. Santa Cruz Biotechnology (U.S.)
7.13.1. Overview
7.13.2. Product Portfolio
7.13.3. Key Innovation Sector
7.13.4. Strategic Initiatives
7.13.5. Scot Analysis
7.13.6. Strategic Analysis
7.14. Mybiosource (U.S.)
7.14.1. Overview
7.14.2. Product Portfolio
7.14.3. Key Innovation Sector
7.14.4. Strategic Initiatives
7.14.5. Scot Analysis
7.14.6. Strategic Analysis
7.15. Biovision (U.S.)
7.15.1. Overview
7.15.2. Product Portfolio
7.15.3. Key Innovation Sector
7.15.4. Strategic Initiatives
7.15.5. Scot Analysis
7.15.6. Strategic Analysis
7.16. Others
7.16.1. Overview
7.16.2. Product Portfolio
7.16.3. Key Innovation Sector
7.16.4. Strategic Initiatives
7.16.5. Scot Analysis
7.16.6. Strategic Analysis

List of Tables
1. Global Bone Morphogenetic Protein Market By Type 2014-2023 ($ Million)
2. Global Rhbmp-2 Bone Morphogenetic Protein Market By Geography 2014-2023 ($ Million)
3. Global   Rhbmp-7 Bone Morphogenetic Protein Market By Geography 2014-2023 ($ Million)
4. Global Bone Morphogenetic Protein Market By Application 2014-2023 ($ Million)
5. Global Spinal Fusion Bone Morphogenetic Protein Market By Geography 2014-2023 ($ Million)
6. Global Trauma Bone Morphogenetic Protein Market By Geography 2014-2023 ($ Million)
7. Global Reconstructive Surgery Bone Morphogenetic Protein Market By Geography 2014-2023 ($ Million)
8. Global Oral-Maxillofacial Bone Morphogenetic Protein Market By Geography 2014-2023 ($ Million)
9. North America Bone Morphogenetic Protein Market 2014-2023 ($ Million)
10. Europe Bone Morphogenetic Protein Market 2014-2023 ($ Million)
11. Asia Pacific Bone Morphogenetic Protein Market 2014-2023 ($ Million)
12. Rest of the World Bone Morphogenetic Protein Market 2014-2023 ($ Million)

List of Figures
1. Global Rhbmp-2 Bone Morphogenetic Protein Market 2014-2023 ($ Million)
2. Global   Rhbmp-7 Bone Morphogenetic Protein Market 2014-2023 ($ Million)
3. Global Spinal Fusion Bone Morphogenetic Protein Market 2014-2023 ($ Million)
4. Global Trauma Bone Morphogenetic Protein Market 2014-2023 ($ Million)
5. Global Reconstructive Surgery Bone Morphogenetic Protein Market 2014-2023 ($ Million)
6. Global Oral-Maxillofacial Bone Morphogenetic Protein Market 2014-2023 ($ Million)
7. United States (U.S.) Bone Morphogenetic Protein Market 2014-2023 ($ Million)
8. Canada Bone Morphogenetic Protein Market 2014-2023 ($ Million)
9. United Kingdom (Uk) Bone Morphogenetic Protein Market 2014-2023 ($ Million)
10. France Bone Morphogenetic Protein Market 2014-2023 ($ Million)
11. Germany Bone Morphogenetic Protein Market 2014-2023 ($ Million)
12. Spain Bone Morphogenetic Protein Market 2014-2023 ($ Million)
13. Roe Bone Morphogenetic Protein Market 2014-2023 ($ Million)
14. India Bone Morphogenetic Protein Market2014-2023 ($ Million)
15. China Bone Morphogenetic Protein Market 2014-2023 ($ Million)
16. Japan Bone Morphogenetic Protein Market2014-2023 ($ Million)
17. Australia Bone Morphogenetic Protein Market2014-2023 ($ Million)
18. Roapac Bone Morphogenetic Protein Market 2014-2023 ($ Million)
19. Latin America Bone Morphogenetic Protein Market 2014-2023 ($ Million)
20. Mena Bone Morphogenetic Protein Market 2014-2023 ($ Million)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Biovision (U.S.)
  • Cellumed Co. Ltd (South Korea)
  • Depuy Synthesis ( U.K.)
  • Ember Therapeutics Inc. (U.S.)
  • Genscript (China)
  • Medtronic Inc. (Ireland)
  • Mybiosource (U.S.)
  • Novus Biological (U.S.)
  • Prospec  (U.K.)
  • R&D Systems (U.S.)
  • Santa Cruz Biotechnology (U.S.)
  • Sigma Aldrich Corporation (U.S.)
  • Sinobiological (China)
  • Stryker Corporation (U.S.)
  • Thermo Fischer Scientific (U.S.)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll